Table 1.
Clinical characteristics of FL patients (n = 187)
| Variable | Training cohort n (%) |
|---|---|
| Age, years (median, range) | 58 (19–87) |
| Sex F/M | 99 (53/8847) |
| Histological gradea | |
| I | 84 (48.8) |
| II | 67 (39) |
| IIIA | 21 (12.2) |
| FLIPIa | |
| 0–1 (Low risk) | 49 (32.9) |
| 2 (Intermediate risk) | 46 (30.9) |
| 3–5 (High risk) | 54 (36.2) |
| Ann Arbora | |
| I | 24 (14.2) |
| II | 18 (10.7) |
| III | 18 (10.7) |
| IV | 109 (64.5) |
| First-line therapy | |
| Never treated | 24 (12.8) |
| Rituximab-based ICT | 98 (52.4) |
| R-CHOP | 68 (69.4) |
| R-Bendamustine | 11 (11.2) |
| R-CVP | 3 (3.1) |
| Others | 16 (16.3) |
| CT without rituximab | 48 (25.7) |
| CHOP | 35 (72.9) |
| Fludarabine-based | 3 (6.3) |
| Others | 10 (20.8) |
| Radiotherapy alone or with rituximab | 13 (7) |
| Rituximab alone | 4 (2.1) |
| Maintenance with rituximaba | 73 (39) |
| Response after induction therapy | |
| CR | 87 (53.7) |
| PR | 63 (38.9) |
| NR/Failure | 12 (7.4) |
ICT immunochemotherapy, R rituximab, CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, CVP cyclophosphamide, vincristine, prednisone, CT chemotherapy; CR complete response, PR partial response, NR no response, FLIPI FL International Prognosis Index
aHistological grade was available for 172 (92%) patients; FLIPI was available for 149 (80%) patients; Ann Arbor was available for 169 (90%) patients; Maintenance was calculated for 147 (79%) patients